Description
U-TEST is a non-invasive diagnostic method for the early detection of sepsis biomarkers in newborns.
Sepsis causes 18 % neonatal deaths, but current diagnosis relies on invasive blood tests that carry risks, are not suitable for frequent use and can lead to overtreatment or misdiagnosis. There is currently no reliable, non-invasive diagnostic method available. U-TEST allows the detection of biomarkers in urine, offering a safer, reproducible alternative to neonatal intensive care units.
In Latvia alone, around 1800 cases are registered each year, with an average cost of €40 000, which justifies the need for safer and more cost-effective diagnostics. U-TEST reduces invasive procedures, overuse of antibiotics, medical waste and supports the EU's objectives of health equity, sustainability and innovation.
Achievable results
To develop a new device for diagnostics based on dried urine spots (DUS), making analysis safer and more convenient for use in intensive care units.
Benefit
A new, non-invasive method for early detection of sepsis in newborns using dried spot urine samples instead of invasive blood tests.
Faster and more accurate diagnosis, allowing doctors to make timely and informed decisions and initiate the most appropriate treatment, reducing the risk of mortality and complications in newborns, who are a particularly vulnerable group of patients.
A solution that will be scalable across hospitals and countries.
